undamentalytics Newsletter
Sign in

Ideaya Biosciences, Inc. cash flow statement

In fiscal 2025, Ideaya Biosciences, Inc.'s operations generated −$71.1m of cash; it spent $2.4m on capital projects, leaving free cash flow of −$73.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−3955−56−87−115−248−71−112
Depreciation and amortisation11222233
Stock-based pay2481218354655
Capital spending10332422
Free cash flow−4155−58−91−118−251−73−114
Free cash flow after stock pay−4351−67−102−136−286−120−169
Shares issued5010186862812740—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IDYA vs PBYIANAB vs IDYAIDYA vs RYTMAKBA vs IDYA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ideaya Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ideaya Biosciences, Inc.